Review
Copyright ©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Transplant. Jun 18, 2021; 11(6): 161-179
Published online Jun 18, 2021. doi: 10.5500/wjt.v11.i6.161
Pediatric metabolic liver diseases: Evolving role of liver transplantation
Jagadeesh Menon, Mukul Vij, Deepti Sachan, Ashwin Rammohan, Naresh Shanmugam, Ilankumaran Kaliamoorthy, Mohamed Rela
Jagadeesh Menon, Ashwin Rammohan, Naresh Shanmugam, Ilankumaran Kaliamoorthy, Mohamed Rela, Institute of Liver Disease and Transplantation, Dr Rela Institute and Medical Center, Chennai 600044, Tamil Nadu, India
Mukul Vij, Department of Pathology, Dr Rela Institute and Medical Center, Chennai 600044, Tamil Nadu, India
Deepti Sachan, Department of Transfusion Medicine, Dr Rela Institute and Medical Center, Chennai 600044, Tamil Nadu, India
Author contributions: Menon J, Vij M, and Sachan D conceptualized the review, performed literature search, and drafting of the manuscript; Vij M, Rammohan A, Shanmugam N, Kaliamoorthy I and Rela M edited and revised the review; all authors read and approved the manuscript for publication.
Conflict-of-interest statement: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Mukul Vij, MD, Doctor, Department of Pathology, Dr Rela Institute and Medical Center, Chromepet, Chennai 600044, Tamil Nadu, India. mukul.vij.path@gmail.com
Received: February 28, 2021
Peer-review started: February 28, 2021
First decision: May 5, 2021
Revised: May 13, 2021
Accepted: June 3, 2021
Article in press: June 3, 2021
Published online: June 18, 2021
Abstract

Metabolic liver diseases (MLD) are the second most common indication for liver transplantation (LT) in children. This is based on the fact that the majority of enzymes involved in various metabolic pathways are present within the liver and LT can cure or at least control the disease manifestation. LT is also performed in metabolic disorders for end-stage liver disease, its sequelae including hepatocellular cancer. It is also performed for preventing metabolic crisis’, arresting progression of neurological dysfunction with a potential to reverse symptoms in some cases and for preventing damage to end organs like kidneys as in the case of primary hyperoxalosis and methyl malonic acidemia. Pathological findings in explant liver with patients with metabolic disease include unremarkable liver to steatosis, cholestasis, inflammation, variable amount of fibrosis, and cirrhosis. The outcome of LT in metabolic disorders is excellent except for patients with mitochondrial disorders where significant extrahepatic involvement leads to poor outcomes and hence considered a contraindication for LT. A major advantage of LT is that in the post-operative period most patients can discontinue the special formula which they were having prior to the transplant and this increases their well-being and improves growth parameters. Auxiliary partial orthotopic LT has been described for patients with noncirrhotic MLD where a segmental graft is implanted in an orthotopic position after partial resection of the native liver. The retained native liver can be the potential target for future gene therapy when it becomes a clinical reality.

Keywords: Liver transplantation, Metabolic liver disease, Tyrosinemia, Wilson disease, Glycogen storage diseases, Urea cycle disorders, Pathology, Auxiliary liver transplant

Core Tip: Metabolic disorders are important cause of morbidity and mortality in children. Their clinical presentations are varied and include end-stage liver disease, hepatocellular cancer, renal tubular acidosis, seizures, encephalopathy, myopathy etc. Liver transplantation (LT) is a curative option in many metabolic disorders. LT is contraindicated in mitochondrial disorders with significant extrahepatic involvement. A combined liver kidney transplant is needed in disorders where the underlying defects significantly damages both the organs. The outcome of LT is excellent in metabolic disorders. Auxiliary partial orthotopic LT is an attractive option as it provides the defective enzymes keeping the native liver intact and may hold an option of withdrawing immunosuppression in case gene therapy can be offered in future.